RWM
DFTX

RMG Wealth Management’s Definium Therapeutics DFTX Stock Holding History

RMG Wealth Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30
Closed -$642 – 661
2026
Q1 		$642 Buy
+30
New +$509 ﹤0.01% 556

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

RMG Wealth Management's DFTX Position: Q2 2026 in Review

RMG Wealth Management sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 30 shares — an estimated $642 sold.

RMG Wealth Management first reported a position in DFTX in Q1 2026 and held it in 1 quarter. The position peaked at $642 in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • RMG Wealth Management reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • RMG Wealth Management sold 30 Definium Therapeutics shares in Q2 2026, an estimated $642.
  • RMG Wealth Management first reported a position in Definium Therapeutics in Q1 2026 and held it in 1 quarter.
  • RMG Wealth Management's Definium Therapeutics position peaked at $642 in Q1 2026.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on RMG Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.